NASDAQ:GLYC - GlycoMimetics Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$16.44 -0.04 (-0.24 %)
(As of 07/23/2018 02:02 AM ET)
Previous Close$16.44
Today's Range$16.34 - $16.95
52-Week Range$10.06 - $26.05
Volume371,386 shs
Average Volume643,348 shs
Market Capitalization$698.65 million
P/E RatioN/A
Dividend YieldN/A
Beta3.43
GlycoMimetics logoGlycoMimetics, Inc., a clinical stage biotechnology company, focuses on the discovery and development of novel glycomimetic drugs to address unmet medical needs resulting from diseases in the United States. Its advanced drug candidate, rivipansel, is a pan-selectin antagonist, which is developed for the treatment of vaso-occlusive crisis in sickle cell disease and has evaluated in a Phase 3 clinical trial, conducted by its strategic collaboration with Pfizer Inc. The company's drug candidate, GMI-1271, an E-selectin antagonist, is evaluated in a Phase 1/2 clinical trial as a potential treatment for acute myeloid leukemia and is in a Phase 1 clinical trial for the treatment of multiple myeloma. It is also developing a Phase 1 clinical trial drug candidate, GMI-1359, a combined CXCR4 and E-selectin antagonist. It has a cooperative research and development agreement with the National Cancer Institute. GlycoMimetics, Inc. was incorporated in 2003 and is headquartered in Rockville, Maryland.

Receive GLYC News and Ratings via Email

Sign-up to receive the latest news and ratings for GLYC and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:GLYC
CUSIPN/A
Phone240-243-1201

Debt

Debt-to-Equity RatioN/A
Current Ratio28.32
Quick Ratio28.32

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual Sales$20,000.00
Price / Sales34,935.00
Cash FlowN/A
Price / CashN/A
Book Value$3.49 per share
Price / Book4.71

Profitability

EPS (Most Recent Fiscal Year)($1.13)
Net Income$-33,280,000.00
Net MarginsN/A
Return on Equity-25.35%
Return on Assets-24.04%

Miscellaneous

Employees40
Outstanding Shares42,500,000
Market Cap$698.65

GlycoMimetics (NASDAQ:GLYC) Frequently Asked Questions

What is GlycoMimetics' stock symbol?

GlycoMimetics trades on the NASDAQ under the ticker symbol "GLYC."

How were GlycoMimetics' earnings last quarter?

GlycoMimetics Inc (NASDAQ:GLYC) posted its earnings results on Thursday, May, 3rd. The biotechnology company reported ($0.33) earnings per share for the quarter, missing analysts' consensus estimates of ($0.28) by $0.05. View GlycoMimetics' Earnings History.

What price target have analysts set for GLYC?

5 brokerages have issued 12-month price targets for GlycoMimetics' shares. Their forecasts range from $21.00 to $35.00. On average, they anticipate GlycoMimetics' stock price to reach $28.25 in the next year. This suggests a possible upside of 71.8% from the stock's current price. View Analyst Ratings for GlycoMimetics.

What is the consensus analysts' recommendation for GlycoMimetics?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for GlycoMimetics in the last year. There are currently 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy."

Who are some of GlycoMimetics' key competitors?

Who are GlycoMimetics' key executives?

GlycoMimetics' management team includes the folowing people:
  • Ms. Rachel K. King, Pres, CEO & Director (Age 59)
  • Mr. Brian M. Hahn, CFO & Sec. (Age 44)
  • Dr. John L. Magnani, Sr. VP of Research, Chief Scientific Officer & Director (Age 65)
  • Dr. Helen M. Thackray, Sr. VP of Clinical Devel. & Chief Medical Officer (Age 50)
  • Mr. Henry Flanner, VP of Technical Operations

Has GlycoMimetics been receiving favorable news coverage?

News stories about GLYC stock have been trending somewhat positive this week, according to Accern Sentiment Analysis. The research firm identifies negative and positive press coverage by monitoring more than 20 million blog and news sources in real time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. GlycoMimetics earned a coverage optimism score of 0.20 on Accern's scale. They also gave news coverage about the biotechnology company an impact score of 49.55 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the stock's share price in the next several days.

How do I buy shares of GlycoMimetics?

Shares of GLYC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is GlycoMimetics' stock price today?

One share of GLYC stock can currently be purchased for approximately $16.44.

How big of a company is GlycoMimetics?

GlycoMimetics has a market capitalization of $698.65 million and generates $20,000.00 in revenue each year. The biotechnology company earns $-33,280,000.00 in net income (profit) each year or ($1.13) on an earnings per share basis. GlycoMimetics employs 40 workers across the globe.

How can I contact GlycoMimetics?

GlycoMimetics' mailing address is 9708 MEDICAL CENTER DRIVE, ROCKVILLE MD, 20850. The biotechnology company can be reached via phone at 240-243-1201 or via email at [email protected]


MarketBeat Community Rating for GlycoMimetics (NASDAQ GLYC)

Community Ranking:  2.9 out of 5 (star star)
Outperform Votes:  193 (Vote Outperform)
Underperform Votes:  144 (Vote Underperform)
Total Votes:  337
MarketBeat's community ratings are surveys of what our community members think about GlycoMimetics and other stocks. Vote "Outperform" if you believe GLYC will outperform the S&P 500 over the long term. Vote "Underperform" if you believe GLYC will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 7/23/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.